Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 08, 2023 15:37 ET | Source: Spherix Global Insights

Spherix Global Insights Amplifies the Lupus Patient Voice, Highlighting the Lengthy and Challenging Journey to Diagnosis and Treatment

Exton, Pennsylvania, Nov. 08, 2023 (GLOBE NEWSWIRE) -- [Exton PA, November 8, 2023] — Spherix Global Insights recently conducted research with 306 Systemic Lupus Erythematosus (SLE) patients,...
October 04, 2023 03:00 ET | Source: Spherix Global Insights

In a Push to Limit Use of Glucocorticoids, US and EU5 Rheumatologists are Increasingly Turning to GSK’s Benlysta and AstraZeneca’s Saphnelo for the Treatment of Moderate-to-Severe Systemic Lupus Erythematosus, According to Spherix Global In

Exton, Pennsylvania, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Prior to the initial approval of Benlysta in 2011, systemic lupus erythematosus (SLE) patients and prescribers had limited options for the...
August 07, 2023 08:35 ET | Source: GRI Bio, Inc.

GRI Bio Presents Encouraging Preclinical Data Indicating Oral Administration of GRI-0803 Inhibited Lupus Nephritis and Significantly Improved Overall Survival in Animal Models

Data presented at The Autoimmunity Conference hosted by the Federation of American Societies for Experimental Biology (FASEB) GRI-0803 in development with an initial focus on the treatment...
July 27, 2023 16:00 ET | Source: Spherix Global Insights

Market Access Issues Hindering Specialists’ Use of Advanced Systemics in Lupus Nephritis

Exton, Pennsylvania, July 27, 2023 (GLOBE NEWSWIRE) -- While the approvals of GSK’s Benlysta (belimumab) and Aurinia’s Lupkynis (voclosporin) have provided rheumatologists and nephrologists with...
June 28, 2023 07:37 ET | Source: ZyVersa Therapeutics

ZyVersa Therapeutics Announces Publication in Clinical Immunology Demonstrating Association Between Renal NLRP3 Inflammasome Activation and Lupus Nephritis Disease Activity

Lupus Nephritis (“LN”) is characterized by inflammation in the kidney, protein leakage into the urine (“proteinuria”), and progressive kidney damageNLRP3 inflammasomes were extensively activated in...
March 17, 2023 05:30 ET | Source: Future Market Insights Global and Consulting Pvt. Ltd.

Lupus Nephritis Treatment Market is expected to accumulate a value of US$ 5.67 Billion by registering a CAGR of 11% in the forecast period 2023 to 2033 | Future Market Insights, Inc.

NEWARK, Del, March 17, 2023 (GLOBE NEWSWIRE) -- During the forecast period 2023 to 2033, the Lupus Nephritis Treatment Market is expected to grow at a value of 11% CAGR, according to Future Market...
March 02, 2023 07:00 ET | Source: Growth Plus Reports

Lupus Nephritis Market Size (2022-2030) Share, Industry Trends, Growth, Challenges and Forecast: Growth Plus Reports

Newark, New Castle, USA, March 02, 2023 (GLOBE NEWSWIRE) -- According to the deep-dive market assessment study by Growth Plus Reports, the global lupus nephritis market was valued at US$ 1.9 billion...
February 10, 2022 09:54 ET | Source: American Kidney Fund

Looped In on Lupus Nephritis: American Kidney Fund’s Campaign Focuses on Preventing, Detecting and Managing Lupus Nephritis

ROCKVILLE, Md., Feb. 10, 2022 (GLOBE NEWSWIRE) -- The American Kidney Fund (AKF) today announces its Looped In on Lupus Nephritis campaign, which is aimed at improving diagnosis, awareness and...
July 19, 2021 20:10 ET | Source: DelveInsight Business Research LLP

Lupus Nephritis Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Lupus Pipeline Comprising a Broad Spectrum of Molecular Targets

Las Vegas, USA, July 19, 2021 (GLOBE NEWSWIRE) -- Lupus Nephritis Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Lupus Pipeline Comprising a Broad Spectrum of Molecular Targets ...
November 10, 2020 16:05 ET | Source: Equillium

Equillium Reports Third Quarter 2020 Financial Results and Business Highlights

LA JOLLA, Calif., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders,...